Ceapro Inc. to Present at the H.C. Wainwright Global Life Sciences Conference
Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF), a Canadian biotechnology company specializing in active ingredients for healthcare and cosmetics, announced its participation in the H.C. Wainwright Global Life Sciences Conference on March 9-10, 2021. CEO Gilles Gagnon will present and engage in one-on-one meetings with investors. A video webcast of the presentation will be available on-demand starting March 9, 2021, at 7:00 AM ET, accessible for 90 days on the company's website.
- None.
- None.
EDMONTON, Alberta, March 03, 2021 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that Gilles Gagnon, President and Chief Executive Officer of Ceapro will present at the virtual H.C. Wainwright Global Life Sciences Conference taking place March 9-10, 2021.
In addition to the presentation, management will also be available to participate in virtual one-on-one meetings with qualified members of the investor community who are registered to attend the conference. For more information about the conference, please visit the conference website here.
The video webcast presentation will be available for viewing on-demand beginning Tuesday, March 9, 2021, at 7:00 AM ET for those registered for the event and will be accessible on the IR Calendar page of the Investors section of the Company's website (www.ceapro.com) and will be archived for 90 days following the event.
About Ceapro Inc.
Ceapro Inc. is a Canadian biotechnology company involved in the development of proprietary extraction technology and the application of this technology to the production of extracts and “active ingredients” from oats and other renewable plant resources. Ceapro adds further value to its extracts by supporting their use in cosmeceutical, nutraceutical, and therapeutics products for humans and animals. The Company has a broad range of expertise in natural product chemistry, microbiology, biochemistry, immunology and process engineering. These skills merge in the fields of active ingredients, biopharmaceuticals and drug-delivery solutions. For more information on Ceapro, please visit the Company’s website at www.ceapro.com.
For more information contact:
Jenene Thomas
JTC Team, LLC
Investor Relations and Corporate Communications Advisor
T (US): +1 (833) 475-8247
E: czo@jtcir.com
Issuer:
Gilles R. Gagnon, M.Sc., MBA
President & CEO
T: 780-421-4555
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release
FAQ
When is Ceapro's presentation at the H.C. Wainwright Global Life Sciences Conference?
Who is presenting for Ceapro at the conference?
Is the presentation available for on-demand viewing?
Where can I find more information about Ceapro's presentation?
What is the stock symbol for Ceapro?
